Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty technology, as well as on-going investment in product development and clinical studies.
Johnson & Johnson Development joined existing prominent investors New Enterprise Associates, Delphi Ventures, Versant Ventures, and Meritech Capital Partners in this financing.
Bill Facteau, president and CEO of Acclarent, said: “The addition of Johnson & Johnson Development together with the support of our existing financial partners will enable Acclarent to continue executing on our strategy to build the preeminent ENT Company.”